Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Molecular Cancer

Figure 2

From: Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin

Figure 2

Activity of agonistic fully human anti-TRAIL death receptor monoclonal antibodies Mapatumumab and Lexatumumab in MPM cell lines or primary cultures. MPM cell lines or primary cultures were treated with 0.01 μg/ml, 1 μg/ml and 10 μg/ml Mapatumumab or Lexatumumab, and cell proliferation was determined by MTT assay 72 h thereafter. Absorbance values obtained with untreated cells maintained under identical conditions were taken as 100%. Representative data of three independent experiments showing similar results are shown here.

Back to article page